American Association for Cancer Research
Browse

Supplementary Figure 2 from Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis

Download (72.98 kB)
journal contribution
posted on 2023-03-30, 19:26 authored by Xiaohong Leng, Tian Ding, Hui Lin, Yan Wang, Limei Hu, Jianhua Hu, Barry Feig, Wei Zhang, Lajos Pusztai, W. Fraser Symmans, Yun Wu, Ralph B. Arlinghaus
Supplementary Figure 2 from Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis

History

ARTICLE ABSTRACT

Lipocalin 2 (LCN2; also known as NGAL) is a secreted glycoprotein and its elevated expression has been observed in breast cancers. However, the importance of LCN2 in breast tumorigenesis is unclear. Here, we employed a spontaneous mammary tumor mouse model showing that MMTV-ErbB2(V664E) mice lacking mouse LCN2 had significantly delayed mammary tumor formation and metastasis with reduced matrix metalloproteinase-9 activity in the blood. LCN2 expression is upregulated by HER2/phosphoinositide 3-kinase/AKT/NF-κB pathway. Decreasing LCN2 expression significantly reduced the invasion and migration ability of HER2+ breast cancer cells. Furthermore, injecting an anti-mouse LCN2 antibody into mice bearing established murine breast tumors resulted in significant blockage of lung metastasis. Our findings indicate that LCN2 is a critical factor in enhancing breast tumor formation and progression possibly in part by stabilizing matrix metalloproteinase-9. Our results suggest that inhibition of LCN2 function by an inhibitory monoclonal antibody has potential for breast cancer therapy, particularly by interfering with metastasis in aggressive types of breast cancer. [Cancer Res 2009;69(22):8579–84]

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC